<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863213</url>
  </required_header>
  <id_info>
    <org_study_id>SARA-08</org_study_id>
    <secondary_id>EudraCT: 2008-006095-30</secondary_id>
    <nct_id>NCT00863213</nct_id>
  </id_info>
  <brief_title>Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation</brief_title>
  <acronym>SARA</acronym>
  <official_title>Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacio Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectivity and safety of atrial fibrillation
      ablation, in comparison to antiarrhythmic drug therapy in patients with refractory,
      persistent atrial fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from atrial arrhythmias, lasting more than 24 hours or requiring cardioversion.</measure>
    <time_frame>1-year follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from atrial arrhythmias (lasting more than 30 seconds) without antiarrhythmic drugs.</measure>
    <time_frame>1-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in frequency and duration of atrial fibrillation or atrial flutter recurrences.</measure>
    <time_frame>1-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in atrial fibrillation/atrial flutter related hospital admissions</measure>
    <time_frame>1-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improve in quality of life measured with standard questionary for Atrial Fibrillation: AF-QoL.</measure>
    <time_frame>1-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in need of cardioversions</measure>
    <time_frame>From 3rd to 12th months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of atrio-ventricular node ablation</measure>
    <time_frame>1-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of crossover to the other arm of the study (only when primary end point has been reached)</measure>
    <time_frame>1-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of a new intervention or ablation during blanking period</measure>
    <time_frame>Until 3rd month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of asymptomatic episodes by Reveal XT</measure>
    <time_frame>1-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of any complications in the acute phase or during follow-up</measure>
    <time_frame>1-year follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atrial Fibrillation Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial fibrillation ablation</intervention_name>
    <description>Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.
It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested.</description>
    <arm_group_label>Atrial Fibrillation Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drug</intervention_name>
    <description>Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.</description>
    <arm_group_label>Drug therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with persistent atrial fibrillation (more than 7 days, or less than 7 days
             needing pharmacologic or electric cardioversion)

        Exclusion Criteria:

          -  Hypo or hyperthyroidism

          -  Persistent atrial fibrillation lasting more than 1 year or non-defined duration

          -  Hypertrophic myocardiopathy

          -  Implantable defibrillation or pacemaker implanted

          -  Moderate or severe mitral valve disease or mitral prosthetic valve

          -  Ejection fraction less than 30%

          -  Left atrial anteroposterior diameter more than 50 mm.

          -  Previous atrial fibrillation ablation

          -  Contraindication to anticoagulation

          -  Left atrium thrombus

          -  Current infective disease or sepsis

          -  Pregnant women

          -  Current unstable angor

          -  Acute myocardial infarction in last 3 months

          -  Atrial fibrillation secondary to ionic disturbance, thyroids disease or secondary to
             any other reversible or non cardiovascular disease

          -  Reduced expectancy of life (less than 12 months)

          -  Patient participating in another clinical study that investigates a drug or device

          -  Psychologically unstable patient or denies to give informed consent

          -  Any cause that contraindicate ablation procedure or antiarrhythmic drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lluís Mont, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angel Arenal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Gregorio Marañon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julian Villacastin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep Brugada, prof Md. PHD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <state>Bizkaia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Universitari</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2009</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Josep Lluis Mont Girbau</investigator_full_name>
    <investigator_title>MD Phd</investigator_title>
  </responsible_party>
  <keyword>Catheter Ablation, Radiofrequency</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Antiarrhythmic Drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

